Short facts | |
API | Ketorolac |
Technology | Sublingual |
Indication | Moderate to moderately severe pain |
Development phase | Finalized phase 1 |
Expected filing with FDA | - |
In-house or partnership | In-house |
Unmet need
Opioids are still used unnecessarily in many situations, further fueling the opioid crisis.
Our aim
Based on Orexo´s novel oral formulation technology, the aim is to develop an opioid-level pain relief treatment for short-term pain (up to 5 days) without the risk of addiction.
Differentiation
Results from the exploratory PK-study in healthy volunteers showed significant better PK-profile, such as faster uptake and higher peak, when compared to nasal spray available on the market.